Restylane Lyft is intended to be used for facial tissue augmentation. It is recommended to be used for shaping the contours of the face, the correction of folds and for lip enhancement.

It should be injected into the deep layer of the dermis and/or the surface layer of the subcutis or in the submucosal layer of the lip. For facial areas with limited soft tissue support and soft tissue cover, e.g. the periorbital region, injection into the subcutaneous fatty tissue or supraperiostal administration are recommended.

The addition of lidocaine provides a pain relieving effect during treatment

Composition:-

• Stabilised hyaluronic acid 20 mg/mL
• Lidocaine hydrochloride 3mg/ml
• Phosphate buffered saline q.s.

Indication: Cheeks.

Disposable sterile 29G TW (thin-walled) needles are provided. In case a replacement needle is required a 27G needle should be used.

Alternatively, a sterile blunt cannula 23-25G can be used. The size and the length of the cannula will affect the force needed to extrude the gel. If a thinner cannula is used the resistance during injection may be too high resulting in an increased risk for leakage or separation of the cannula and syringe. The same considerations are applicable for needles.

(Formerly Restylane Perlane)

We provide Galderma (U.K.) Limited with certain information on who has purchased their products through this website for consumer service/support and safety purposes. A copy of Galderma’s Privacy Notice explaining how your data will be collected, used, and disclosed by Galderma can be found here https://tinyurl.com/galdermaprivacy

Adverse events should be reported

For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

For Ireland, suspected adverse events can be reported via HPRA Pharmacovigilance, www.hpra.ie

Adverse events should also be reported to Galderma (UK) Ltd.

E-mail: Medinfo.uk@galderma.com Tel: +44 (0) 300 3035674